Blue Gene - History

History

In December 1999, IBM announced a US$100 million research initiative for a five-year effort to build a massively parallel computer, to be applied to the study of biomolecular phenomena such as protein folding. The project had two main goals: to advance our understanding of the mechanisms behind protein folding via large-scale simulation, and to explore novel ideas in massively parallel machine architecture and software. Major areas of investigation included: how to use this novel platform to effectively meet its scientific goals, how to make such massively parallel machines more usable, and how to achieve performance targets at a reasonable cost, through novel machine architectures. The initial design for Blue Gene was based on an early version of the Cyclops64 architecture, designed by Monty Denneau. The initial research and development work was pursued at IBM T.J. Watson Research Center.

In 1999 Alan Gara moved from Columbia University, were he had been leading work on the QCDOC architecture to the IBM T.J. Watson Research Center. The QCDOC system was a special purpose computer for QCD computations; it used a chip with an embedded PowerPC core on it. At IBM, Alan Gara started working on an extension of the QCDOC architecture into a more general-purpose supercomputer: The 4D nearest-neighbor interconnection network was replaced by a network supporting routing of messages from any node to any other; and a parallel I/O subsystem was added. DOE started funding the development of this system and it became known as Blue Gene/L (L for Light); development of the original Blue Gene system continued under the name Blue Gene/C (C for Cyclops) and, later, Cyclops64.

In November 2001, Lawrence Livermore National Laboratory (LLNL) joined IBM as a research partner for Blue Gene. Development proceeded at IBM T.J. Watson Research Center and at IBM Rochester with the goal of delivering a system to LLNL.